Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964. In 2025 Lidoflazine has also been reported to interact with tubulin and inhibit its polymerization.[2]


Physical properties

Solubility at room temperature

Extracted from[1]

Solvent 0.01

N

 0.1

N

% pH % pH
Hydrochloric Acid 0.4 3.0 0.7 1.9
Tartaric Acid 0.3 3.1 1.0 2.5
Citric Acid 0.3 3.1 0.5 2.5
Lactic Acid 0.2 3.4 0.7 2.9
Acetic Acid 0.1 3.5 0.4 3.8

References

  1. 1 2 Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. doi:10.1016/S0022-3565(25)27319-0. PMID 5944369.
  2. ↑ Baksheeva VE, La Rocca R, Allegro D, Derviaux C, Pasquier E, Roche P, Morelli X, Devred F, Golovin AV, Tsvetkov PO (2025). "NanoDSF Screening for Anti-tubulin Agents Uncovers New Structure–Activity Insights". Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.5c01008.

Further reading

  • Schaper WK, Xhonneux R, Jageneau AH (November 1965). "Stimulation of the coronary collateral circulation by lidoflazine (R 7904)". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 252 (1): 1–8. doi:10.1007/bf00246424. PMID 4222721. S2CID 31959581.

[1]


  1. ↑ Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB (June 2011). "Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules". Acta Pharmacologica Sinica. 32 (6): 781–788. doi:10.1038/aps.2011.70. PMC 4085723. PMID 21623390.
source: https://en.wikipedia.org/wiki/Lidoflazine